<p>Nkgen Biotech Inc. reported no revenues for the years ended December 31, 2024 and 2023. The company continues to incur operating losses and negative cash flows from operations. Provision for income taxes decreased by less than $0.1 million for the year ended December 31, 2024 compared to the previous year, primarily due to changes in deferred tax balances partially offset by valuation allowances. The company expects to continue incurring significant expenses as it advances its research and clinical trials. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001845459-25-000004), on October 08, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here</p>

NKGN

<p>Nkgen Biotech Inc. reported no revenues for 2023 and 2024, continuing to incur operating losses and negative cash flows. The provision for income taxes decreased slightly due to changes in deferred tax balances. The company anticipates ongoing significant expenses as it progresses with its research and clinical trials.</p>

Nkgen Biotech reports no product revenue for 2023 and 2024